Game of thrones: immunotherapy versus molecular targeted therapy in renal cell cancer scenarios

Objectives Treatment for advanced renal cell carcinoma (RCC) has become increasingly more complex over the last several years. Objective 1 is to which treatment option is immunotherapy, targeted therapy, or the combination of immunotherapy with targeted therapy the best for patients? Objective 2 is...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	International urology and nephrology Ročník 51; číslo 12; s. 2107 - 2117
Hlavní autoři:	Cetin, Bulent, Kosar, Alim
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	Dordrecht Springer Netherlands 01.12.2019 Springer Nature B.V
Témata:	Aged Carcinoma, Renal Cell - therapy Clear cell-type renal cell carcinoma Clinical trials Clinical Trials as Topic Decision making Drug development Female Humans Immune checkpoint inhibitors Immunotherapy Kidney cancer Kidney Neoplasms - therapy Male Medicine Medicine & Public Health Metastases Metastasis Middle Aged Molecular Targeted Therapy Monoclonal antibodies Nephrology Patients Risk groups Targeted cancer therapy Tyrosine Urology Urology - Review Vascular endothelial growth factor Metastatic renal cell carcinoma Immunotherapy Tyrosine kinase inhibitors
ISSN:	0301-1623, 1573-2584, 1573-2584
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!